Precision MedicineRecent studies link GLP-1 receptor agonists with lower risks of tuberculosis, serious infections, infection-related hospitalisation and mortality in people with type 2 diabetes.
An international study involving more than 7 million people found that patients with type 2 diabetes taking GLP-1 drugs had a lower risk of developing tuberculosis compared with those using other antidiabetic medicines.
Upcoming Conferences and EventsTogether, the findings add to growing evidence suggesting potential protective associations between GLP-1 medications and infection-related outcomes, particularly serious infections.
The researchers proposed that GLP-1 receptor agonists could influence infection susceptibility through mechanisms extending beyond blood glucose control.
Further research will be needed to establish whether GLP-1 medications directly reduce infection risk.
Precision Medicine
Recent studies link GLP-1 receptor agonists with lower risks of tuberculosis, serious infections, infection-related hospitalisation and mortality in people with type 2 diabetes.
Recent research suggests that GLP-1 receptor agonists may offer benefits beyond metabolic and cardiovascular health, with studies linking their use to lower risks of tuberculosis and serious infections among people with type 2 diabetes.
An international study involving more than 7 million people found that patients with type 2 diabetes taking GLP-1 drugs had a lower risk of developing tuberculosis compared with those using other antidiabetic medicines. The hazard ratio was 0.49 compared with DPP-4 inhibitors, 0.53 with sulfonylureas, 0.60 with metformin and 0.82 with SGLT2 inhibitors.
"These findings suggest that beyond their established metabolic benefits, GLP-1 receptor agonists may confer additional advantages in lowering infection risk," Chih-Cheng Lai, MD, of Chi Mei Medical Center in Taiwan, and colleagues concluded in Nature Communications.
A separate real-world study of more than 50,000 US adults with type 2 diabetes and atherosclerotic cardiovascular disease found that tirzepatide was associated with lower one-year risks of infection-related mortality, infection-related hospitalisation, urinary tract infections and infections across care settings compared with sitagliptin.
The study, led by researchers including Nils Krüger, MD, of Harvard Medical School, also observed lower all-cause mortality among patients taking tirzepatide.
Upcoming Conferences and Events
Together, the findings add to growing evidence suggesting potential protective associations between GLP-1 medications and infection-related outcomes, particularly serious infections. Researchers noted that people with diabetes face an increased risk of active tuberculosis and poorer outcomes following infection, while obesity has also been associated with infection-related mortality.
The researchers proposed that GLP-1 receptor agonists could influence infection susceptibility through mechanisms extending beyond blood glucose control. Preclinical and translational research has suggested possible effects on immune function, including neutrophil activity, bacterial clearance and innate immune responses.
However, the studies were observational and had limitations, including incomplete information on tuberculosis-related clinical factors, geographical differences in TB epidemiology and relatively short follow-up in the tirzepatide analysis. Further research will be needed to establish whether GLP-1 medications directly reduce infection risk.
Discover the "One plausible explanation that our study supports is the substantial reduction in serious bacterial infections observed among individuals who initiated tirzepatide, suggesting that part of the survival benefit may reflect effects beyond atherosclerotic mechanisms," wrote Krüger and colleagues.Together, the findings add to growing evidence suggesting potential protective associations between GLP-1 medications and infection-related outcomes, particularly serious infections. Researchers noted that people with diabetes face an increased risk of active tuberculosis and poorer outcomes following infection, while obesity has also been associated with infection-related mortality.The researchers proposed that GLP-1 receptor agonists could influence infection susceptibility through mechanisms extending beyond blood glucose control. Preclinical and translational research has suggested possible effects on immune function, including neutrophil activity, bacterial clearance and innate immune responses.However, the studies were observational and had limitations, including incomplete information on tuberculosis-related clinical factors, geographical differences in TB epidemiology and relatively short follow-up in the tirzepatide analysis. Further research will be needed to establish whether GLP-1 medications directly reduce infection risk.Discover the latest health news and emerging precision medicine news shaping the future of healthcare.
